市場調査レポート

肺動脈高血圧症(PAH)治療の世界市場

Pulmonary Arterial Hypertension (PAH) Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 248901
出版日 ページ情報 英文 287 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
肺動脈高血圧症(PAH)治療の世界市場 Pulmonary Arterial Hypertension (PAH) Therapeutics
出版日: 2012年07月01日 ページ情報: 英文 287 Pages
概要

当レポートでは、肺動脈高血圧症(PAH)治療の世界市場を取り上げ、米国、カナダ、日本、欧州、アジア太平洋、ラテンアメリカおよびその他の地域など、地域ごとの個別分析を行うとともに、過去の実績/推定および予測、ならびにこれらの市場の過去6年間の分析を提供し、主要企業およびニッチ企業26社のプロフィールをまとめるなど、概略以下の構成でお届けします。

第1章 イントロダクション、調査方法、製品定義

  • 調査の信頼性とレポートの制約
  • 免責事項
  • データの解釈とレポートのレベル
    • 定量技法および分析法
  • 製品の定義と調査範囲

第2章 エグゼクティブサマリー

  • 産業概要
    • 成長への道をたどっている世界のPAH市場
    • PAH市場の発展
    • WHO(世界保健機関)によるPAH患者のグループ分け
    • ニューヨーク心臓協会(NYHA)によるPAH患者の分類
    • 市場の見通し
    • 競合シナリオ
    • 市場の動向および課題
    • 安定成長に向かっているPAH薬剤市場
    • Tracleerが依然として誰もが認めるリーダー
    • TracleerはERA受容体に関わってLetairisに押される見込み
    • 経口治療が世界のPAH治療市場を推進
    • ThelinがPAH市場から撤退
    • パイプライン薬剤がTracleerに厳しい競争を強いる
    • 多様なPAH薬剤クラスに関する洞察
    • 比較コスト分析
    • 主な統計
    • 投与モード別の主要な認可薬剤
    • メカニズム別の主要なPAH薬剤
    • 認可/発売年別の主要なPAH薬剤
    • 主要なPAH薬剤の特許期限
    • 主要なPAH薬剤に関する洞察
    • Tracleer(Bosentan)
    • Revatio (Sildenafil)
    • Ventavis (Iloprost)
    • Letairis (Ambrisentan)
    • Veletri (Epoprostenol)
    • Flolan (Epoprostenol)
    • Remodulin (Treprostinil)
    • Tyvaso (Treprostinil)
    • Adcirca (Tadalafil)
      • 開発中の薬剤
    • 近く投入される主要な有望薬剤
    • Macitentan
    • Riociguat
    • Selexipag
    • パイプラインにおける治験
    • United TherapeuticsがFREEDOMを完了:経口RemodulinのM治験
    • ActelionがSERAPHINフェーズIII治験を完了
    • GeNO LLCがNITROSYL?のPHiano治験を開始
    • ArenaがAPD811のフェーズI治験を完了
    • GileadがCicletanineのフェーズIIを開始
    • AMBITIONフェーズIV治験の開始
    • Bayerが経口RiociguatのフェーズIIIを開始
    • PHIRST-1治験に関するフェーズIII結果が公表される
    • 好ましい結果を得られたIMPRESフェーズIII治験
    • SelexipagがGRIPHONのフェーズIII治験を実施中
  • 製品概要
    • イントロダクション
    • PAHサブグループ
    • PAHの原因と進行
    • PAHの症状
    • PAHの診断
    • 臨床的背景における患者の特定
    • PAHの検出
    • PAHの評価および分類
    • PAHの治療
    • PAHの新たな治療法
  • 戦略的沿革
  • 製品/サービスの発表
  • 主要な企業
    • Actelion Pharmaceuticals Ltd.(スイス)
    • Arena Pharmaceuticals, Inc.(米国)
    • Bayer HealthCare Pharmaceuticals(ドイツ)
    • Cipla Limited(インド)
    • 第一三共(日本)
    • Eli Lilly and Company(米国)
    • Gilead Sciences, Inc.(米国)
    • GlaxoSmithKline Plc(英国)
    • 日本新薬(日本)
    • Pfizer, Inc.(米国)
    • Sanofi S.A(フランス)
    • The Novartis Group(スイス)
    • United Therapeutics Corp.(米国)
    • YM BioSciences, Inc.(カナダ)
  • 世界市場の展望

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • その他欧州
  • アジア太平洋
  • ラテンアメリカ
  • その他の地域

第4章 競合情勢

目次
Product Code: MCP-7500

This report analyzes the worldwide markets for Pulmonary Arterial Hypertension (PAH) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. European market for PAH Therapeutics is further analyzed by the following countries/regions - France, Germany, Italy, UK, Spain, and Rest of Europe. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 26 companies including many key and niche players such as Actelion Pharmaceuticals Ltd., Arena Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Cipla Limited, Daiichi Sankyo Co., Ltd., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Nippon Shinyaku Co., Ltd., Pfizer, Inc., Sanofi S.A, The Novartis Group, United Therapeutics Corp., and YM BioSciences, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Global PAH Market on a Growth Trajectory
  • Evolution of the PAH Market
    • Table 1: Global PAH Market by Drug Class: 2011 (includes corresponding Graph/Chart)
  • The PAH Classification by WHO and NYHA
  • PAH Patient Groupings as per World Health Organization
  • Classification of PAH patients As per New York Heart Association (NYHA)
  • Market Outlook
  • Competitive Scenario
    • Table 2: Leading Drugs in the PAH Market by Sales: 2011 (includes corresponding Graph/Chart)
  • Market Trends & Issues
  • PAH Drug Market on a Steady Growth Trajectory
  • Tracleer Remains the Undisputed Leader
    • Table 3: Market Share of Leading PAH Oral Drugs (2012): Percentage Breakdown of Value Sales for Tracleer, Revatio, Letairis/Volibris and Others (includes corresponding Graph/Chart)
  • Tracleer to lose ground to Letairis over ERA Receptors
  • Oral Therapies lead the Global PAH Therapeutics Market
    • Table 4: Global PAH Market by Mode of Drug Usage (2012): Percentage Share Breakdown for Oral, Inhaled, and Injectables (includes corresponding Graph/Chart)
  • Thelin Exits PAH Market
  • Pipeline Drugs to Give Tough Competition to Tracleer
  • An Insight into Different PAH Drug Classes
    • Table 5: Global PAH Market (2011): Percentage Share Breakdown by Cost Effectiveness of PAH Drugs (includes corresponding Graph/Chart)
    • Table 6: Global PAH Market (2011): Percentage Breakdown for Patients on Single Therapy - PDE5 Inhibitor, ERA, Inhaled Prostacyclin Analog, Injectable Prostacyclin Analog, and Others (includes corresponding Graph/Chart)
    • Table 7: Global PAH Market (2011): Percentage Share Breakdown for Patients on Combination Therapies (includes corresponding Graph/Chart)
  • Comparative Cost Analysis
    • Table 8: Annual Costs Involved in Major Approved PAH Drugs (includes corresponding Graph/Chart)
  • Key Statistics
  • Leading Approved Drugs as Per Mode of Administration
  • Leading PAH Drugs by Mechanism
  • Leading PAH Drugs by Year of Approval/Launch
  • Patent Expiries of Select Major PAH Drugs
  • An Insight into Select PAH Drugs
  • Tracleer (Bosentan)
    • Future Dominance Likely, Even as New Drugs Line up for Launch
  • Revatio (Sildenafil)
  • Ventavis (Iloprost)
  • Letairis (Ambrisentan)
  • Veletri (Epoprostenol)
  • Flolan (Epoprostenol)
  • Remodulin (Treprostinil)
  • Tyvaso (Treprostinil)
  • Adcirca (Tadalafil)
    • Pipeline Drugs
  • Select Promising Imminent Drugs
  • Macitentan
  • Riociguat
  • Selexipag
  • Clinical Trials in the Pipeline
  • United Therapeutics Completes FREEDOM - M Trial for Oral Remodulin
  • Actelion Completes SERAPHIN Phase III Trial
  • GeNO LLC Begins PHiano Trial for NITROSYL™
  • Arena Completes Phase I trial for APD811
  • Gilead Starts Phase II of Cicletanine
  • AMBITION Phase IV Trial to Begin
  • Bayer Begins Phase III for Oral Riociguat
  • Phase III Results Out for PHIRST-1 Trial
  • Phase III IMPRES trial Ends on a Positive Note
  • Selexipag under Phase III GRIPHON Trial

2. PRODUCT OVERVIEW

  • Introduction
  • PAH Subgroups
    • Table 9: Global PAH Market (2011): Gender-wise Percentage Share Breakdown by Incidence of Occurrence (includes corresponding Graph/Chart)
  • Causes and Development of PAH
  • Symptoms of PAH
  • Diagnosis of PAH
  • Identification of patients on clinical grounds
  • Detection of PAH
  • Evaluation and classification of PAH
  • Treatments for PAH
  • Novel Therapies for PAH

3. STRATEGIC CORPORATE DEVELOPMENTS

  • FDA Revises Boxed Warning for Letairis Tablets
  • Pfizer Secures Approval for Revatio® from European Commission for Treating PAH in Pediatric Patients
  • Sanofi-Aventis Changes Name to Sanofi
  • Novartis Secures Regulatory Approval for Onbrez® Inhalation Capsules
  • Nippon Shinyaku and Actelion Pharmaceuticals Ink License Agreement for Macitentan
  • Pfizer Receives European Regulators Approval for Viagra to Treat PAH in Children
  • Ergonex Pharma and Pfizer Sign Agreement for Terguride
  • Aires Pharmaceuticals and Novartis International Pharmaceutical Sign Agreement
  • Lee's Pharmaceutical Receives Exclusive Rights to Market Remodulin
  • Invida Group and Actelion Pharmaceuticals Extend Contract
  • Immune Control Merges with Arginetix
  • Pfizer Signs Agreement with Ergonex Pharma to Acquire Terguride Investigational PAH Treatment
  • Pulmokine Receives NIH SBIR Grants for PAH Treatment Development
  • FDA Grants Orphan Drug Designation to Clinical Data PRX-8066 Serotonin 2B Receptor Antagonist
  • US FDA Approves VELETRI® Brand Name for Epoprostenol for Injection Therapy of Actelion Pharmaceuticals US
  • US Food and Drug Administration Approves Additional Guidelines for Veletri Administration
  • Actelion Pharmaceuticals US Selects Accredo Health Group as Exclusive Specialty Pharmacy Provider of Epoprostenol for Injection
  • European Commission Approves Revatio IV Formulation for Treating Pulmonary Arterial Hypertension
  • United Therapeutics Withdraws Marketing Authorization Application for Tyvaso
  • Navitas Assets and Gilead Sciences Ink Agreement
  • Actelion Pharmaceuticals Receives FDA Approval for Tracleer®
  • United Therapeutics Secures US FDA Approval for TYVASO Inhalation Solution
  • Eli Lilly Inks License and Supply Agreement with United Therapeutics
  • United Therapeutics Secures US FDA Approval for ADCIRCA™ Tablets
  • Actelion Signs Definitive Agreement with GeneraMedix
  • Eli Lilly Japan Obtains Approval to Commercialize Adcirca Tablet
  • Proteo's Drug Candidate Elafin Obtains Orphan Drug Status for Treating Esophagus Carcinoma
  • Pfizer to Withdraw Thelin from Market
  • Actelion Acquires Improved Epoprosterol Sodium formulation from GeneraMedix
  • United Therapeutics' Tyvaso Receives FDA Approval
  • United Therapeutics' Adcirca Receives US FDA Approval
  • Actelion's Tracleer Drug Receives Approval from EU
  • Pfizer's Revatio Receives US-FDA Approval
  • Actelion's new Ventavis® formulation Receives Approval from US FDA
  • Gilead Sciences and GlaxoSmithKline Enter into Collaboration
  • United Therapeutics Inks Licensing Deal with Supernus Pharmaceuticals
  • Lung to Fund Aradigm Study of Treprostinil in AERx Inhaler
  • Aires Pharmaceuticals Inks Exclusive License Agreement with National Institutes of Health
  • United Therapeutics and Lung Rx Submit New Drug Application to FDA
  • GlaxoSmithKline Receives Marketing Authorization for Volibris® from European Commission

4. PRODUCT/SERVICE LAUNCHES

  • United Therapeutics Introduces Adcirca™ in Canada
  • GlaxoSmithKline Introduces Volibris Oral Tablets for PAH
  • Cipla Introduces BOSENTAS
  • Actelion Pharmaceuticals US Introduces Pulmonary Arterial Hypertension Mobile Reference Guide
  • Actelion Pharmaceuticals US Introduces Ventavis in New Formulation
  • Nippon Shinyaku Introduces Adcirca® Tablets 20mg

5. FOCUS ON SELECT PLAYERS

  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Arena Pharmaceuticals, Inc. (US)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Cipla Limited (India)
  • Daiichi Sankyo Co., Ltd. (Japan)
  • Eli Lilly and Company (US)
  • Gilead Sciences, Inc. (US)
  • GlaxoSmithKline Plc (UK)
  • Nippon Shinyaku Co., Ltd. (Japan)
  • Pfizer, Inc. (US)
  • Sanofi S.A (France)
  • The Novartis Group (Switzerland)
  • United Therapeutics Corp. (US)
  • YM BioSciences, Inc. (Canada)

6. GLOBAL MARKET PERSPECTIVE

    • Table 10: World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 11: World Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 12: World 15-Year Perspective for Pulmonary Arterial Hypertension (PAH) Therapeutics Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • Table 13: World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics by Drugs - Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, Thelin (Sitaxentan) & Tracleer), Prostacyclin (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso & Ventavis), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics by Drugs - Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, Thelin (Sitaxentan) & Tracleer), Prostacyclin (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso & Ventavis), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 15: World 15-Year Perspective for Pulmonary Arterial Hypertension (PAH) Therapeutics Market by Drugs - Percentage Breakdown of Dollar Sales for Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, Thelin (Sitaxentan) & Tracleer), Prostacyclin (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso & Ventavis), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat) Markets for Years 2004 through 2009 for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • US PAH Drug Market Treads on a Growth Path
      • FDA Approved PAH Drugs in the US
    • Table 16: PAH Market in the US (2011): Market Share Breakdown for Leading Oral PAH Drugs by Value (includes corresponding Graph/Chart)
    • Prospective Market for Combination Therapies in the US
    • Table 17: PAH Market in the US by Drug Class (2011): Percentage Share Breakdown for ERA, PDE5, PGI2, PDE5+ERA, PGI2+PDE5, PGI2+ERA, PGI2+PDE5+ERA and Others (includes corresponding Graph/Chart)
    • Oral Remodulin Likely to Emerge as a Niche Market for Class II and III Market in the US
    • Table 18: PAH Market in the US (2011): Class of PAH Patients - Class II, Class III, Class I and Class IV (includes corresponding Graph/Chart)
    • Table 19: PAH Market in the US (2011): Percentage Share Breakdown by Volume for Class of PAH Patients - Class II, Class III, Class I and Class IV (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
    • Product/Service Launches
    • Focus on Select Key Players
  • B. Market Analytics
    • Table 20: The US Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 21: The US Historic Review for Pulmonary Arterial Hypertension Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current & Future Analysis
    • Product/Service Launch
    • Focus on Select Player
  • B. Market Analytics
    • Table 22: Canadian Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 23: Canadian Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
      • Select Approved and Pipeline Drugs in Japanese PAH market
    • Strategic Corporate Developments
    • Product/Service Launches
    • Focus on Select Players
  • B. Market Analytics
    • Table 24: Japanese Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 25: Japanese Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
    • Focus on Select Major Players
  • B. Market Analytics
    • Table 26: European Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 27: European Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 28: European 15-Year Perspective for Pulmonary Arterial Hypertension (PAH) Therapeutics Market by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, the UK, Spain and the Rest of Europe for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 29: France Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 30: France Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
    • Bayer Healthcare Pharmaceuticals - A Key Player
  • B. Market Analytics
    • Table 31: German Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 32: German Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 33: Italian Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 34: Italian Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 35: The UK Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 36: The UK Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 37: Spanish Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 38: Spanish Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 39: Rest of European Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 40: Rest of European Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
    • Product/Service Launch
    • Focus on Select Player
  • B. Market Analytics
    • Table 41: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 42: Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 43: Latin American Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 44: Latin American Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 45: Rest of World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 46: Rest of World Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top